Matthew Lowrie, quality assurance manager, Almac Clinical Technologies explores how the evolving regulatory guidance around data integrity is impacting clinical trial applications and data.
Zabir Macci, director of eCOA business strategy & sales engineering at IQVIA, describes how to navigate global regulatory guidance for successful multinational clinical trials.
Last Thursday, chancellor Jeremy Hunt announced new measures for smoother medicine approvals in the UK, increased support for R&D, and a simplified tax system for SMEs. UK biotech company, Nevrargenics shared its position on the 2023 Budget.
2023 will bring new regulatory changes linked to process digitalisation and automation, REPHINE’s Dr. Eduard Cayón discusses the implications for quality control and how pharma companies can stay ahead of the curve.
A recent panel debate moderated by Christian K. Schneider, head of Biopharma Excellence, explored emerging approaches to clinical research and data collection for therapies linked to rare diseases.
Michael Sassano, founder, CEO and chairman of the board, Somai Pharmaceuticals, discusses the European medical cannabis sector, and its impact on pharmaceuticals, alongside the challenges that Somai aims to address.
Deloitte’s Patrick Middag and Dennie van de Voort provide some practical steps to creating and entrenching effective data governance practices which in turn can help elevate the quality and value of regulated pharma data.
Punya Abbhi, COO at Celegence, explains how the adoption of digital technologies enables companies to manage their regulatory compliance requirements in a more efficient and reliable manner.
EPM sat with Marivi Mendizabal, vice president Quality and Regulatory, Cytiva, as she explains how government policy and regulatory trends impact the biopharma industry, and how collaborating with the government can enhance biopharma resilience.
Chris Allen, CEO of UK-based analytical testing and scientific consultancy provider Broughton, explains the challenges — and opportunities — that Brexit holds for laboratory services.
Datwyler Healthcare's Tabassam Sharif, regulatory affairs manager and Eugene Polini, technical key account manager, explain how parenteral packaging suppliers are optimising their technologies and processes to meet regulatory requirements.
Rebekah Jordan shares her view from the seat at the Editor’s Desk on what impact the post-Brexit era might have on the UK process of medicine approvals and how external pharma manufacturers may respond.
